Still Looking For A Cancer Vaccine Breakthrough, Roche Signs $200m Vaccibody Deal

Claims First Neoantigen Clinical Response In Advanced Cancer

 
• By Andrew McConaghie
  
Genetech
Genentech is forging ahead with neoantigen-targeting cancer vaccines, despite a recent disappointment with its BioNTech partnership
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip